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Abstract  
 
Introduction/Aims:  Human papillomavirus (HPV) is the most common sexually 
transmitted agent worldwide, being also responsible for 5% of all human cancers.  Even though 
cervical cancer’s incidence is decreasing, HPV-driven anogenital and head and neck cancers are 
increasing. Differences in the natural history of HPV have been observed by gender and anatomic 
sites of infection, where genetic expression, hormonal responses, epithelial backgrounds and tissue 
stromal microenvironments may play a crucial role. The main goal of this study was to observe if 
E6, E7 and E5 HPV oncoproteins could trigger distinct grades in the HPV-related carcinogenic 
pathways in the K14-HPV16 mouse model, on the most affected human anatomic sites of infection 
namely in the uterine cervix, base of tongue, anus, penis and bladder.  
Methods:  Samples from the base of the tongue, anus, uterine cervix and bladder were 
collected from ten K14-HPV16 female mice, 30-weeks-old. Alongside, samples from the base of the 
tongue, anus and penis were collected from ten K14-HPV16 male mice, 30-weeks-old. Matched 
samples of E6, E7 and E5 mRNA levels were quantified by real-time PCR, after normalization using 
the best two housekeeping genes. Histopathological analysis of the tissues was performed for tissue 
characterization. Tissue samples were classified as normal, low-grade squamous intraepithelial 
lesion, high-grade squamous intraepithelial lesion and squamous cell carcinoma. Statistical analysis 
was performed using the IBM SPSS Statistics. Kruskal-Wallis and Mann-Whitney tests were used 
to evaluate statistical differences in normalized relative expression (–ΔCt) of the E6, E7 and E5 genes 
among the different tissue samples.  
Results:  The expression pattern of the oncogenic HPV viral mRNAs E6, E7 and E5 was 
similarly detected across tissues (p>0,05), except in the bladder (p< 0.01). However, we observed a 
higher incidence of more advanced lesions, namely high squamous intraepithelial lesions and 
squamous cell carcinoma in the base of the tongue when compared with the other studied anatomic 
sites. In uterine cervix and bladder samples, only normal epithelium was observed. Alongside, in the 
base of the tongue, the female K14-HPV16 developed 50% more squamous cell carcinoma than their 
male counterparts. 
Conclusion: This study suggests that the carcinogenesis induced by HPV in the oropharyngeal 
region is earlier and less dependent on other external co-factors being more incident in females . In 
the base of the tongue, cancer was induced within the mice 30 weeks period, in comparison with the 
other anatomic locations, where HPV itself seems not to be sufficient to promote more advanced 
lesions even though the expression of the viral mRNAs was similarly detected within the tissues.  
Future studies should focus on understanding the behaviour of the HPV oncoproteins and the related 
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oncogenic pathways at multiple anatomic locations of infection, representing different tissue 
microenvironments. This might allow a better understanding of tissue-specific HPV-related 
carcinogenic steps and the development of precision therapies.  
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I. General Introduction  
 
1.1. Human papillomavirus and cancer  
 
Viruses are among the most prominent risk factors for cancer development (1). Human 
papillomavirus (HPV) itself is the most common sexually transmitted agent worldwide, afflicting 
50-80% of the sexually active human population (2). It is also responsible for one-third of all the 
tumours induced by viruses and accounts for 5% of all human cancers, being one of the most 
powerful human carcinogen  (1). This translates in approximately 630.000 new  HPV-related cancer 
cases per year,  being therefore, a huge public health burden (3).  
Since HPV identification as the cause of cervical cancer, achieved by Harald Zur Hausen, 
who was awarded the 2008 Nobel Prize in Physiology/Medicine, this area has been an intensive focus 
of research.  Hausen and colleagues pursued the idea that if tumour cells contained an oncogenic 
virus, they should harbour viral deoxyribonucleic acid (DNA) integrated into their genome (4). In 
1983, Hausen found integrated HPV-DNA not only in genital cancer biopsies but also in cell lines 
derived from cervical cancer, discovering the high-risk HPV16 (4,5) (Figure 1). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. HPV main milestones. 
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1.2. HPV Biology  
 
1.2.1. HPV genome  
 
  HPVs are a small, double-stranded and non-enveloped virus with 50-55 nm in diameter (6). 
Their episomal genome has approximately 8000 base pairs, mostly encoding 8 open reading frames 
(ORFs), expressed from polycistronic messenger ribonucleic acid  (mRNA) (6) (Figure 2).  
 
 
 
 
 
 
 
 
 
 
HPV infects the basal keratinocytes, being its expression temporal and synchronized with 
their differentiation (7). It expresses early and late proteins which are named based on their temporal 
expression in the epithelium. The early region, denoted by “E” which occupies approximately 50% 
of the HPV viral genome, encodes the early proteins E6, E7, E1, E2, E4 and E5 which are crucial for 
viral replication, maturation and transformation (7) (Figure 2). The late region, denoted by “L”, 
which occupies around 40% of the viral genome, encodes the major capsid protein L1 and the minor 
capsid protein L2 that are structural viral proteins vital for virus assembly and release (7) (Figure 2). 
Finally, the long control region (LCR), covering only 10% of the HPV genome, contains   1) the viral 
promoter p97, crucial for the expression of the early viral proteins, 2) the origin of viral DNA 
replication, 3) several binding sites of transcription factors like SP-1, AP-1 and the transcription 
factor TATA binding protein (TFIID), essential in the regulation of viral expression and 4) cis-
sequences that regulate mRNA stability, polyadenylation and numerous alternative splicing  
mechanisms  (8) (Figure 2). In the E7/E1 ORF region, a p670 promotor is found, which is important 
in encoding the viral mRNA during the HPV genome amplification and viral escape steps in the 
upper layers of the epithelium (7) (Figure 2). 
Figure 2. HPV16 episomal genome. HPV16 genome can be 
grouped into three main regions: 1) An early region, 
encoding the early proteins E6, E7, E1, E2, E4, E5; 2) a late 
region, encoding the late proteins L1 and L2 and 3) a long 
control region (LCR), that comprises the origin of 
replication and influences several transcriptional factors. 
Adapted from (7) . 
HPV16 
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1.2.2. HPV evolution   
 
HPVs belong to the Papillomaviridae family, one of the most ancient viral families, with at 
least 350 million years old, affecting a diverse range of animal species, including humans (9) (Figure 
3).  HPV is highly heterogeneous and according to the American Cancer Society, more than 300 
genotypes of papillomavirus (PVs) have been identified, 200 of them capable of infecting humans. 
Nevertheless, HPV is highly conserved, showing a divergence rate of 1% at every 40.000-80.000 
years (10).  
  
 
 
 
 
 
 
 
 
 
 
 
Figure 3. Papillomavirus evolutionary tree with a 350 million years old common ancestor of reptiles, amphibious 
and mammals. Adapted from (11). 
 
 HPV is grouped within 5 evolutionary branches, named according to the Greek alphabet, 
namely the alfa, beta, gamma, nu and mu papillomaviruses (α, β, γ, µ, and ν respectively) (Figure 
4). The largest and the clinically most important HPV group, the α-HPV, comprises 64 HPVs, being 
able to infect the reproductive, oral and anogenital mucosae and therefore responsible for the 
development of high-grade lesions that can progress to cancer (12).  
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The α-HPV can be subdivided into two major subgroups, namely the low-risk HPVs (e.g. 
HPV6 and 11) mainly associated with the development of warts and benign lesions (13) and the high-
risk HPVs (e.g. HPV16  and 18) which are considered the main drivers of high-grade lesions’ 
development and consequently cancer progression due to its stronger binding and function to its 
molecular targets leading to a higher differential and transformation properties (12). HPV16 itself 
has a great ability to persist and promote malignant transformation, higher than any other HPV type. 
It is also the most prevalent HR-HPV being found in approximately 50% of the cervical cancers and 
more than 85% of HPV-induced anal and head and neck cancers (14).  
 
 
Figure 4. Evolutionary relationships between the HPV genera, namely the alfa, beta, gamma, nu and mu papillomavirus.  
Adapted from (12). 
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1.3. HPV viral proteins  
 
1.3.1. Main drivers of oncogenesis  
 
Even though all genes encoded by HPV are necessary for its life cycle and regulation, the 
E6, E7 and E5 oncoproteins are essential for the malignancy process of HPV-positive carcinomas 
(15). Therefore, it is crucial to identify and understand how these viral oncoproteins contribute to the 
all known cancer cell alterations allowing the progression of the carcinogenesis (15) (Table 1). 
(Hallmarks of HPV carcinogenesis: the role of E6, E7 and E5 oncoproteins in cellular malignancy. 
BBA Gene Regulatory Mechanisms, submitted review). 
 
1.3.1.1. E6 oncoprotein 
The E6 protein is one of the well-established and recognized oncoproteins that are associated 
with the malignant progression of HPV-infected cells.  It has 18 kDa and 2 zinc-binding motifs, being 
mainly found in the nucleus (16). The HPV oncoproteins can abrogate the apoptosis mechanisms, 
allowing the infected cells with genomic errors to resist cell death.  From all the roles promoted by 
the E6 oncoprotein, the most important and studied is the degradation of the p53 guardian of the 
genome protein, a transcription factor that regulates apoptosis, DNA repair and the cell cycle (17). 
The E6 oncoprotein targets and interacts with the conserved LxxLL consensus sequences of the 
Ubiquitin-protein ligase E3A (UBE3A) also known as ubiquitin ligase E6-Associated Protein (E6-
AP), that works as a connected bridge between the E6 oncoprotein and its primary target, the p53, 
targeting it  for proteasomal degradation (Figure 5) (17). Other cellular targets of E6 have also been 
identified (Table 1). 
  
          
 
 
 
 
Figure 5. Ubiquitination and consequent proteasomal degradation of p53 by the formation of a complex ternary E6-AP; E6; 
p53. 
. 
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1.3.1.2. E7 oncoprotein  
E7 is a small phosphoprotein with approximately 16 kDa and three conserved regions (CR1, 
CR2 and CR3) (18). It was the first HPV malignant oncoprotein to be discovered, being found in the 
nucleus (19). The CR2 regions of E7 contain an LXCXE motif that is important in the association of 
its transforming targets, namely the retinoblastoma protein (pRB), a regulator of the cell cycle control 
(20). Expression of E7 leads to the degradation of the pRB tumour suppressor protein targeting it for 
proteossomal degradation through the ubiquitonation pathway, deregulating cellular replication (20) 
(Figure 6). The real damage of the unbalanced expression of E6 and E7 viral proteins happens when 
these two proteins are expressed simultaneously, leading to cell immortalization (21,22). 
 
 
 
 
 
 
 
 
 
Figure 6. Cell cycle regulation of pRB and E2F in a) normal cells and in b) HPV-infected cells. A) In normal cells, during 
the G1 phase, the unphosphorylated pRB protein binds to the transcription factor E2F and concomitantly recruits histone 
deacetylases (HDACs) to target promotor sequences of E2F, therefore repressing the expression of proliferating genes, 
cyclin A (CCNA1) and cyclin E (CCNE1). b) in HPV infected cells, E7 targets the pRB protein for degradation, inhibiting 
the binding with the transcription repressor E2F and consequently not recruiting the HDACs, allowing the transcription of 
the proliferating genes (23). 
 
1.3.1.3. E5 oncoprotein 
Although the major transforming activities in the HPV-related lesions are led by the 
oncoproteins E6 and E7, the 10 kDa transmembrane protein E5, mainly localized in the intracellular 
membranes of the endoplasmic reticulum and Golgi apparatus, also plays an important role  (24).     
The oncogenic properties of E5 protein have always been limited, however, recent studies have 
shown its pivotal importance, particularly in cell transformation and immune modulation, that 
together with oncoproteins  E7 and E6 helps in the cell malignant progression (25). One of the most 
important roles of E5 oncoprotein is its interaction with the major-histocompatibility-complex 
(MHC), important in the activation of the immune system (26).  
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E5 promotes the retention of the MHC class I in the Golgi apparatus, inhibiting its 
transportation to the cell surface, fact that leads to a decreased ability of the complex to recognize 
the HPV viral antigens and therefore activate the immune system (26).  Other functions in the HPV 
viral life cycle and in the malignant progression have also been identified (Table 1). 
 
 
Table 1. Main functions and targets of E6, E7 and E5 HPV oncoproteins.     Downregulation;    upregulation;       action 
blocking 
High-risk 
Viral 
protein 
Cellular 
location 
Function Main targets Expression 
level 
References 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
E6 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Nucleus and 
cytoplasm 
 
 
Escaping cell death 
P53 protein  (17) 
Pro-caspase 8 
protein  
 (27) 
Bak protein   (28) 
TNR1  (29) 
Fas/Fas ligand death 
pathway  
 (30) 
NF-κB; cIAP-2  (31) 
Deregulation of 
cell cycle 
P300/CBP complex 
protein  
 (32) 
miR34a  (33) 
Immune system 
modulation 
IRF3  (34) 
IFNα  (35) 
IFNκ  (36) 
Cell 
Immortalization 
NFX1-91  (37) 
Myc  (38) 
Sp1  (39) 
Genomic 
instability 
APOBEC3  (40) 
XRCC1  (41) 
 
 
Cell invasion 
Dlg  (42) 
SCRIB  (43) 
MAGI-1, MAGI-2 
and MAGI-3 
 (44) 
PAR3  (45) 
Fibulin-1  (46) 
miR-23b  (47) 
Paxillin disruption  (48) 
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E7 
 
 
Nucleus 
 
Deregulation of 
cycle cell 
pRB protein   (49) 
p107/p130  (49) 
P21           (50) 
P27            (50) 
Claspin   (51) 
E2F6   (52) 
Immune system 
modulation 
TLR9  (53) 
Cgas-STING  (54) 
 
Genomic 
instability  
Abnormal 
centrosome 
synthesis  
 (55) 
γ-tubulin  (56) 
CDK2   (57) 
 
 
 
 
 
 
E6/E7 
 
 
 
 
 
 
 
 
Nucleus and 
cytoplasm  
 
Deregulation of 
cellular energetics  
Aerobic glycolysis   (58) 
mTORC1  (59) 
GLUT-1  (60) 
 
 
Genomic 
instability: 
epigenetic 
deregulation  
DNMT1 
DNMT3A 
DNMT3B 
  
(61) 
E-cadherin   (62,63) 
CXCL14  (64) 
CCNA1  (65) 
CBP/p300  (66) 
TIP60  (67) 
ADA3   (68) 
Inflammation 
promotion 
IL-6  (69) 
IL18   (70) 
 
Angiogenesis 
switch  
Maspin   (71) 
Thrombospondin-1   (71) 
VEGF  (71) 
IL-8  (71) 
 
E5 
 
Endoplasmic 
reticulum and 
Golgi apparatus 
Sustaining 
Proliferative 
signalling 
EGFR  (72) 
ATPase  (73) 
KGFR/FGFR2b  (74) 
Escaping cell death  Bax protein  (75) 
Cell invasion  MET  (76) 
Immune system 
modulation  
MHC-class I  (26) 
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1.3.2. Other HPV viral proteins  
 
HPV expresses other early and late proteins that are essential for its life cycle such as early 
viral proteins E2, E1 and E4 and the late viral proteins L1 and L2. Their functions will be briefly 
mentioned.  
1.3.2.1. E2 viral protein 
The E2 protein has approximately 48 kDa, being mainly found in the nucleus (77). It is 
important not only in the recruitment of the E1 protein to the HPV origin site of replication but also 
in the regulation of E6 and E7 expression (78). This protein, particularly in the initial stages of HPV 
infection, binds to the transcription sites near the E6 and E7  promoter regions, downregulating their 
expression to a low copy number, just enough to push cells to be mitotically active, but not sufficient 
to activate the immune system (79). When E2 is disrupted, mainly by HPV integration in the host 
genome but also by hypermethylation mechanisms, the negative feedback of this protein onto the E6 
and E7 genomic region is repressed (78). This fact leads to an unbalanced expression of E6 and E7 
oncoproteins and consequent oncogenic transformation of the infected cells, that has been shown to 
be reversed by E2 reintroduction into cervical carcinoma cells (80).  
 
1.3.2.2. E1 viral protein 
The E1 viral protein has about 70-80 kDa in size, being the largest papillomavirus protein 
(81). It is probably the most important protein in the HPV life cycle since it is essential for the 
initiation of viral DNA replication (82). It is also the only HPV protein with enzymatic activity (82). 
It has the main function of encoding a DNA helicase, unwinding DNA and consequently making it 
accessible for cellular replication proteins. Furthermore, it also has ATPase activity and the ability 
to recruit host cells’ replication proteins like DNA polymerases, topoisomerases I and alpha-primases 
(82,83).  
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1.3.2.3. E4 viral protein 
The E4 protein, with 17 kDa,  plays an important role in maturation and virus escape from 
the epithelial surface (84). E4 viral proteins are mainly found in the cytoplasm, but can also be present 
in the cell nucleus (84). It is also believed that this protein can promote the collapse of the cellular 
cytokeratin network, facilitating the viral escape (85). Although the E4 viral protein is considered an 
early protein, its function and expression are mainly associated with later stages of the infection.  
 
1.3.2.4. L1 major capsid protein  
The major capsid L1 protein, with 55 kDa, comprises 72 pentamers and is essential in capsid 
formation and self-assembling into a virus-like-particle (VLP), forming a virion that contains 360 
copies of the L1 protein (86). L1 protein is also important in the interaction of HPV with the target 
basal cell, leading to viral cell entry (87).  Due to its pivotal role in the formation of viral capsids as 
well as its high conservation status, it has been the main target in the development of HPV 
prophylactic vaccination (88). 
 
1.3.2.5. L2 minor capsid protein 
The L2 minor capsid protein has 80 kDa, being highly conserved (89). L2 structural viral 
protein not only plays a key role in virus assembly and infection but also in the transportation of the 
viral particles to the cytosol as well as the HPV genome to the nucleus (90).  
 
 
1.4. HPV infection pathway  
 
HPV is highly epitheliotropic, only establishing a productive infection in the stratified 
epithelial keratinocyte cells, being rarely detected in other types of cells (12).  It targets the basal 
keratinocytes stem cells, the only ones that are able to actively divide (12). These infected 
keratinocytes stem cells are mainly found in the bulge of the hair follicle or even at the transformation 
zone in the uterus between the ecto- and the endocervix, assuring a continuous reservoir of HPV 
infected cells (91).  
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 The probable cause of infection is the existence of micro-lesions in the reproductive, anogenital 
and oral area, being the infection transmitted mainly during sexual activity (92). However, HPV 
vertical transmission from mother to child can also be possible (93).  Even though most sexually 
active people will be infected by HPV at some part of their life’s, most of these infections will be 
cleared by their immune system within a period from 24-36 months (88). 
 
1.4.1. Keratinocyte-dependent infection  
 
The epithelia is comprised of several types of keratinocytes (K), that are found in the different 
layers of the epithelium, comprehending 90% of all epidermis cell types (94). While K14 and K5 are 
found in the basal membrane, in the spinous and granular epidermis layers, K1 and K10 are the most 
common ones (95). Keratinocytes can have two fates: they can be stem cells’ keratinocytes, having 
the capability of undefined self-renewal, or can be basal transit amplifying keratinocytes cells. The 
former ones, after mitotic activity, migrate upwards in the epithelia, becoming differentiated and 
forming the upper layers of the epidermis, ensuring skin stability and protection against the exterior 
environment (96). However, the suprabasal HPV-infected cells fail to withdraw from the cell cycle 
as well as to become completely differentiated, continuing to proliferate due to the HPV viral 
expression.  
1.4.2. HPV binding and endocytosis  
 
Initially, HPV, through the L1 protein, targets the basal keratinocytes by binding to the 
glycoproteins heparan sulfate proteoglycans´ (HSPGs) receptor, found on the surface of most cells 
(97). This binding will promote the first conformational change in the HPV viral capsid (98).  
Posteriorly, the first conformation change will lead to the N-terminus of the HPV L2 protein to be 
cleaved by furin, which consequently exposes the L2 binding site to a more specific secondary 
cellular receptor, which is not yet identified, having as possible candidates the Epithelial Growth 
Factor Receptor (EGFR) or the integrin α-6 on the membrane of the target cell (99). This last 
mechanism is decisive for viral particles´ internalization, leading to the activation of the pathways 
necessary for HPV endocytosis (100) (Figure 7). 
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1.4.3. Virus uptake and nucleus delivery  
 
HPV is internalized by a clathrin or caveolin-mediated endocytic mechanism dependent on 
the L1 viral protein (101). The most recent studies enlighten that after cell internalization, HPV 
travels through the endosomal organelles from the early to the late endosomes (102). These 
organelles, characterized by a low pH, promote viral coat disassembly and L1 and L2 dissociation 
(87).  HPV then travels through the trans-Golgi network and the endoplasmic reticulum until it finally 
reaches the nucleus (87). The HPV entry into the nucleus occurs by nuclear envelope breakdown in 
prometaphase, where the viral DNA associates with the condensed chromosomes using the microtube 
spindle (103).  
 
 
 
 
 
Epidermal cell  
HPV  
Heparin Sulfate   
Secondary receptor  
Furin 
Figure 7. Infectious pathway of HPV. Due to the existence of micro-lesions, HPV infects the cutaneous and mucosal 
sites in several anatomic regions. Initially, HPV binds to the HSPGs at the basal membrane of the cells, resulting in the 
first conformation change in the HPV capsid. Posteriorly, the furin protein will cleave the N-terminal region of the L2 
minor capsid protein, leading to a second transformation change in the capsid. The L2 viral protein will then be exposed 
to a secondary receptor, leading to viral internalization, which happens either by clathrin or caveolin-mediated endocytic 
mechanism. 
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1.5. HPV life cycle  
 
1.5.1. Basal HPV replication  
 
After a successful infection and travel to the nucleuos, HPV is extrachromosomal, depending 
on cellular replication to encode the genes for its life cycle. The first viral genes to be expressed, in 
basal cells, although at a low copy number (50–100 copies per cell), are E6 and E7 oncoproteins 
(79). These oncoproteins are important in pushing the cells to be mitotically active mainly by the 
impairment of important regulatory cellular pathways (104,105) (Table 1). Alongside, expression of 
E1 and E2 proteins occurs and this step is crucial to the highjack of the host cellular replication 
molecules (82,83). 
1.5.2. HPV genome amplification 
 
Posteriorly, in the middle-upper epithelial layers, as HPV-infected keratinocytes undergo 
differentiation and lose their mitotic activity, the HPV late promoter p670 becomes activated (7). 
This promoter increases the expression of the HPV viral proteins (at least 1000 copies per cell), 
leading to viral DNA amplification (7). The HPV genome amplification step is crucial to ensure that 
the differentiated cells, as they move upwards the epithelium, are sustained in the S-phase like state, 
allowing HPV to continue its life cycle (79). 
 
1.5.3. Virus release 
 
In the last phase of the HPV life cycle, a higher expression of the early protein E4 and the 
late proteins L1 and L2 occurs in the upper layers of the epithelium, allowing not only the collapse 
of the cellular cytokeratin structure but also the packing of HPV genome in infectious virions (85,86). 
This step is coincident with the shedding of the more mature keratinocytes, which leads to virus 
release (7). HPV infection is, therefore, an orchestrated event of differential gene expression that 
ensures smooth progression and limits immune system activation (Figure 8).  
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1.6. HPV carcinogenesis 
 
1.6.1. HPV integration  
 
The carcinogenesis driven by HPV infection is not the aim but rather the result of two 
mechanisms that not only represent a “dead end” for the virus but also to the development of lesions. 
These two mechanisms englobe an accidental viral DNA integration in the host genome, potentially 
triggered by the genomic instability caused by the expression of the viral oncoproteins E6 and E7, 
which increases the double strand break incidence in the host cells (106,107). Even though HPV 
integration can happen  across all the human genome, it is more common in chromosomal fragile 
regions such as 3q28, 4q13.3, 8q24.21, 13q22.1 17q21 regions, near clusters of microRNAs as well 
as microhomology regions (1-10 bp) between the host and the virus (108,109).  
 
 
Figure 8. HPV life cycle. a) HPV infects the basal layer of the epithelium through micro-lesions b) At this level, HPV 
is episomal, depending on cellular replication for encoding the necessary genes for HPV life cycle. E6 and E7 expression 
is needed throughout the infection, pushing cells to be mitotically active. Additionally, expression of E1, E2, E4 and E5 
is crucial for viral amplification. L1 and L2 proteins are expressed in upper epithelial layers c) Accidental integration or 
hypermethylation mechanisms leads to an unbalanced expression of E6 and E7 and consequently to the development of 
high-grade lesions that can progress to cancer. 
 
 
 
 
 
  
Dermis  
Basal  
Spinous  
Granular   
Cornified    
Epidermal cell  HPV infection   E6/E7 viral proteins   E1/E2/E4/E5 proteins   L1/L2 viral proteins   
Integration/Hypermethylation   
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In the HPV genomic region, the E2 ORF is usually the most affected location by the 
integration process, however other genomic regions like E1 as well as L1 and L2 can be affected, 
leaving E6 and E7 oncoproteins as the primary products expressed by the infected cells which will 
promote a selective growth advantage not only due to the enhanced expression of the HPV 
oncoproteins but also because of the altered expression of key cellular genes and changes in the 
methylation patterns, conferring competitive advantage  (110). Alongside, the disrupted E2 HPV 
genomic region will also cease to act as a negative regulator of E6 and E7, promoting their 
unbalanced expression (78). Additionally, mechanisms of HPV  hypermethylation were found to 
block the access of the E2 promotor region, leading to an unbalanced expression of the E6 and E7 
viral oncogenes without E2 disruption (111). Hypermethylation of E2 binding regions can be found 
in approximately 20% of the cervical cancers and 60% of the HPV-positive oropharyngeal cancers, 
in which the virus remains episomal and the E2 genomic region is intact (111,112). 
 
1.7.  HPV-derived lesions’ classification and staging 
 
Persistent high-risk HPV infection can lead to the transformation of the epithelium cells into 
pre-cancerous lesions (104). Those lesions are just the ultimate steps before full malignant 
transformation and consequently the development of squamous cell carcinoma (SCC). Squamous 
intraepithelial lesion (SIL) is the commonly used term to describe lesions related with HPV persistent 
infection.   
 
1.7.1.   Low-Grade Squamous Intraepithelial Lesions  
In low-grade squamous intraepithelial lesions (LGSIL), the epithelium is abnormal with 
slight changes in cell size, shape, and number. However, it continues to be well differentiated with 
no nuclear malformations (113). LGSIL are not considered true precursors of cancer but rather the 
results of the HPV persistent infection. These lesions have a higher probability of regression to 
normal epithelium, (≈70%) and only 10% may progress to more advanced lesions (114) (Figure 9). 
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1.7.2. High-grade Squamous Intraepithelial Lesions 
 
The high-grade squamous intraepithelial lesions (HGSIL), are defined by a higher number 
of precancerous cells on the surface of the epithelium, affecting approximately two-thirds of it (113). 
They have a higher potential of becoming cancerous cells and invade deeper tissues (114) (Figure 
9). During the timeline in which pre-cancerous lesions are progressing,  DNA mutations in oncogenes 
and tumour suppressor genes, chromosomal aberrations, aberrant DNA methylation and 
overexpression of oncogenic miRNAs pave the way for the full malignant transformation (115). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 9. Cancer Lesions progression. a) Normal epithelium, b) LSIL epithelium, with slight changes in cell 
proliferation and shape, affecting approximately one third of the epithelium. c) HSIL epithelium with abnormal 
development of cell growth and differentiation as well as nuclei enlargement and nuclear membrane more 
prominent, affecting approximately two thirds of the epithelia. d) cancerous epithelium with complete cell 
undifferentiation and capability of invading deeper tissues.  
 
 
Normal         LSIL     HSIL
 
    SCC  
70% 30% 
10% 
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1.8. HPV-induced carcinogenesis factors and co-factors 
 
Persistent HPV infection is the most important risk factor for the development of HPV-
derived lesions. However, HPV alone, in some cases, seems not to be a sufficient cause for the full 
development of a malignancy, fact explained by the small percentage of women that develop cervical 
cancer when compared to its infectious rate. Other factors must be present to potentiate full 
malignancy. 
1.8.1. Viral factors   
The development of HPV-derived cancers is dependent on viral factors themselves, namely 
the HPV type that infects the epithelium. The high-risk HPVs, particularly HPV16 and 18, pose a 
greater risk for the development of HGSIL due to their oncogenic potential and prevalence (10). 
Alongside, the high-risk HPV oncoproteins E6, E7 and E5 play a crucial role in the development of 
lesions, impairing key regulatory functions in cell cycle regulation, apoptosis and in the immune 
system (Table 1) (104). 
1.8.2. External co-factors  
 
1.8.2.1. High parity  
  External co-factors also play a significant role in HPV-derived carcinogenesis. High parity 
is consistently considered a risk factor for the development of cervical cancer (116). In fact, a woman 
that had seven or more full pregnancies has a four-fold increased probability of developing this type 
of carcinoma (116). Several reasons may explain this difference. During pregnancy, the cervix 
transformation zone has a higher susceptibility for an infection as well as the hormonal changes that 
can also modulate the progression of the HPV infection (117). 
1.8.2.2. Hormonal contraceptives use  
Another co-factor associated with an increased risk of HPV-derived malignant lesions is the 
long-term use of hormonal contraceptives (118). Alterations in the hormonal mechanisms may 
deregulate HPV infection, leading to an increase risk of the integration status of the virus into the 
human genome (118). Studies have also found that estradiol, a component of hormonal 
contraceptives, may stimulate the transcription of the oncoproteins E6 and E7, leading to an increased 
risk for the development of cervical pre-cancerous lesions (119).  
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Additionally, estrogen and progesterone increase cell proliferation and in cooperation with 
the oncogenic HPV viral proteins, increase the risk of DNA damage particularly in the uterus 
transformation zone where those hormone receptors are particularly frequent (117).  
1.8.2.3. Tobacco 
Tobacco has been identified as a potent factor and co-factor for the development of several 
cancers (120). Women with persistent HPV infection that smoke continuously has one to three-fold 
increase in the risk of developing HPV-related malignancies when compared to non-smokers (121). 
Furthermore, it has also been reported an earlier onset of cervical cancer for patients presenting a 
smoking habit status (122). This may be explained by damages caused in the DNA by the chemical 
and carcinogenic components of cigarettes but also by the consequent decreased ability of the 
immune system to counteract viral infections  (123). 
1.8.2.4. HIV and Chlamydia trachomatis   
HIV and other sexually transmitted agents like Chlamydia trachomatis, considered the most 
common transmitted bacterial infections,   have also been identified as established co-factors that can 
promote the development of HPV-related malignancies, leading to immunocompromised states, with 
a decreased action of the host immune system against the virus (121,124). 
1.8.2.5. Host genetic factors 
Additionally, host factors like the genetic background and the immune system must be taken 
into consideration. A good immune system response will be activated in the presence of a pathogen, 
leading to an increased expression of phagocytes, cytokines and natural-killer cells (125). Taken this 
into account, an immunosuppressed person has an increased risk of an HPV persistent infection and 
consequently the development of malignant lesions (125). Several genetic polymorphisms have been 
identified and associated with an increased probability of developing HPV-related malignancies 
(126–128). One of the most studied has been the p53 tumour suppressor gene rs1042522 (Arg72Pro) 
polymorphism with contradictory results (129,130). The presence of an arginine instead of a proline 
in the codon 72 of p53 may lead to a stronger binding of the E6 to the p53 protein, which in its turn 
promotes an increment of its degradation (129). 
 
 
General Introduction 
 
 21 
1.9. HPV Epidemiology 
 
1.9.1.  Cervical Cancer  
 
   In 1842, the first association between cervical cancer and sexual activity was observed by 
Rigoni-Stern, which stated that prostitutes and married women had a higher incidence of cervical 
cancer when compared to nuns and virgin women. However, it was only after almost 150 years that 
Rigoni-Stern hypothesis was validated by the work of Harald Zur Hausen, in which HPV started 
being linked to the development of cervical cancer (4) (Figure 1). Nowadays, HPV is a well-
established etiological factor for the development of cervical cancer and it is found in virtually 100% 
of those cancers, being approximately 84% of them SCC (131) (Figure 10). HPV usually infects the 
cervical transformation zone, a fragile metaplastic location between the endocervix and the 
ectocervix, which is not only the most sensitive oestrogen location but is also subjected to constant 
changes during the woman´s life and therefore it is believed to facilitate the establishment and the 
persistent of HPV infection and consequently HPV-induced lesions (132). 
 
 
 
 
 
Figure 10. HPV-associated cancer cases in 2012, according to the International Agency for Research on Cancer (IARC). 
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83% of the HPV-related cancers are cervical cancers, the 4th worldwide most common cancer 
in females and the 2nd  worldwide leading cause of cancer in women aged 15-44 (133). Even though 
the scenario seems negative, cervical cancer rates are decreasing in developed countries not only due 
to the increment of screening programs but also because of the implementation of prophylactic 
vaccination against HPV infection (134). However, HPV still remains a huge public health burden, 
especially in non-developed countries, where cervical cancer is still increasing at an alarming rate, 
accounting for 85% of  cervical cancer worldwide (14).  
Non-developed regions like Eastern Africa, Melanesia, Southern Africa and Middle and 
Western Africa have the higher 
incidence of cervical cancer 
(Figure 11). The highest 
mortality rates also belong to the 
previously referred regions, 
where HPV screening programs 
are almost inexistent. On the 
opposite hand, Western Asia, 
Australia/New Zealand, North 
America and Western Europe 
show the lowest incidence rates 
of cervical cancer (Figure 11). In 
Portugal, cervical cancer is the 
10th most common cancer, where 
the most recent report shows 9.0 
cases per 100.000 females, being 
the 23rd European country with 
higher cervical cancer rates (14).  
 
 
 
 
 
 
 
 
 
Figure 11. Worldwide Age-Standardized cervical cancer incidence and mortality per 100.000 females, IARC 
2012. 
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1.9.2.  HPV-induced anogenital cancers  
 
Even though the knowledge of HPV role in the cervical carcinogenesis is well established, 
in anogenital cancers, englobing the vulvar, vaginal, anal and penile cancers it is still limited (135). 
While cervical cancer’s incidence has been decreasing, anogenital HPV-induced cancers are 
increasing (14). According to the international agency for research on cancer (IARC), HPV is the 
worldwide annual cause of 8500 cases of vulvar cancer, 12000 cases of vaginal cancer, 35000 cases 
of anal cancer and 13000 cases of penile cancer (14) (Figure 10).  The most common worldwide 
HPV-related anogenital cancers are anal and penile SCC. In anal carcinomas where 95% represent 
SCC, HPV is found in approximately 85% of the cases (Figure 10), particularly in the anal 
transformation zone between the rectum and the anus,  being the most important factor for the anal 
carcinogenesis and the HPV16 the most prevalent HPV type (136). Women seem to be more 
susceptible to develop anal carcinoma, although HIV-infected men who have sex with men present 
the higher risk (137,138). In penile cancer, HPV is found in approximately 20-30% of the cases 
(Figure 10), being HPV16 also the most prevalent HPV type and SCC representing 95% of the total 
cases (139). However, even though penile HPV infection is common, the development of cancer is 
very rare. Other factors that can lead to the development of this carcinoma are lack of penile hygiene, 
smegma retention and phimosis (140). A distinct molecular pathway is observed between cancers 
derived from these factors or HPV infection, however, due to the fact that penile SCC is very rare, it 
is still much understudied (141). Both HPV-induced anal and penile cancers have particularly high-
incidence in more developed regions like Northern Europe, North America, South America and 
Australia, possibly due to an increase of HPV transmission by sexual behaviour change (142) (Figure 
12). In Portugal, in 2012, the age-standardized incidence rate (ASR) of HPV-positive anogenital 
cancers was 0.9 per 100.000 people. 
Figure 12. Worldwide age-standardized incidence rate (ASR) of anogenital HPV-positive cancer cases per 100.000 
people, both sexes. IARC 2012. 
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1.9.3.  HPV-induced head and neck cancers  
 
Head and neck squamous cell carcinoma (HNSCC) is the fifth most common cancer 
worldwide, afflicting approximately 500.000 people annually, being 90% of the cancers SCC (143). 
Even though most of these cancers are associated with alcohol and tobacco consumption, infection 
by HPV has also been linked with their development, appearing in younger individuals that don´t 
smoke, drink or are immunosuppressed  (144).  
Depending on the anatomic location, HPV prevalence worldwide in HNSCC is 
approximately 20-40% (Figure 10) and reaching as high as 70-80% prevalence in the developed 
world (145). However, it is particularly high in the oropharyngeal anatomic location (≈40%), namely 
in the deep crypts of the palatine, lingual tonsils and base of the tongue compared with the larynx 
and the oral cavity, mainly due to different tissue architectural backgrounds and stromal 
microenvironments (146,147).  In fact, the rate of HPV-induced oropharyngeal  squamous cell 
carcinomas (OPSCC) is increasing so dramatically that in 20-25 years, HPV will be the main 
etiological factor related to the development of this carcinoma (148). Additionally, an increase of 
225% of HPV-induced OPSCC from 1998 to 2004 has been noted compared with a regression of 
50% of those cancers related to alcohol and tobacco consumption (148). However, even though 
oropharyngeal HPV-associated cancers are increasing so dramatically, there is still a huge gap in the 
knowledge of the carcinogenic cascade in this anatomic region when compared with the other HPV-
cancers (Table 2)  
 
 
Table 2. HPV-associated precancerous lesions and SSC 
 Female Male 
 Precancerous lesion Cancer Precancerous lesion Cancer  
Uterine cervix  CIN 3 SCC  
Vagina  VaIN3 SCC 
Vulva VIN3 SCC 
Penis  PIN3 SCC 
Anus  AIN3 SCC AIN3 SCC 
Oropharynx  ? SCC ? SCC 
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Globally, per year, there are an estimated of 38.000 HNSCC cancers attributable to HPV and 
just like HPV-induced anogenital cancers, their incidence not only is increasing but is also higher in 
more developed regions namely North America and Europe (Figure 13). This fast-growing neoplasia 
affects 3 times more males than females from 35-55 years old explained by a higher probability of 
HPV transmission between vagina-oral mucosae rather than penile-oral mucosae, higher number of 
sexual partners by the males but also due to a stronger immunity response of the women that was 
probably previously infected and therefore immune to an HPV oral infection. This risk is even higher 
in women that have sex with women  (149). HPV16 is found in more than 90% of the oropharyngeal 
cancers and it is not clearly understood why this HPV type has a much higher incidence, alongside 
with the anal carcinomas (85%), when compared with the uterine cervix where HPV16 is found in 
only 50% of the cases (150). Tissue microenvironment and specificity or viral preference can be the 
reason. In Portugal, in 2012, the ASR of HPV-positive head and neck cancers was 1 per 100.000 
people. 
 
 
 
 
 
 
 
Figure 13. Worldwide ASR of head and neck HPV-positive cancer cases (oropharynx, oral cavity and larynx) per 100.000 
people, both sexes. IARC 2012 
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1.10. K14-HPV16 mouse model  
 
One of the biggest challenges in the study of the HPV life cycle and carcinogenesis is the 
inexistence of efficient in vitro protocols. As the virus is able to infect different anatomic sites, the 
influence of epithelial backgrounds, the tissue stromal microenvironment, the genetic expression and 
the immune system of the host may play an important role. Nowadays, the inexistence of in vitro 
approaches that mimic and recreate the three-dimension structure of the epithelium, which is crucial 
for virus infection and propagation, as well as animal models that characterize the HPV natural 
infection limits the understanding of the papillomavirus biology infection pathway. The K14-HPV16 
mouse model appears to be one of the best approaches for the study of the carcinogenic cascade 
induced by HPV (151). The FVB/n inbreed mouse background used in this study, not only is 
characterized by a high reproductive performance and large litters but is also more permissive to 
SCC, when compared with other inbreed backgrounds like the C57BL/6, BALB/c and SSIN/SENCAR 
(152).   
The K14-HPV16 model of induced neoplastic progression expresses the early genomic 
region of the high-risk HPV16 from the nucleotide 97 to the 6152, expressing E6, E7, E1, E2, E4 
and E5 proteins (153) (Figure 14) . 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 14. K14-HPV16 genomic construct. 
General Introduction 
 
 27 
 
 The K14, one of the primary keratin proteins found in the basal membrane of stratified 
squamous epithelia is used as a promoter by directing the expression of the viral proteins to this cell 
type, not only mimicking the mechanism of infection but also the HPV-related lesions´ development 
by HPV integration into the host genome. The integration process happens in approximately 80% of 
the uterine cervix and HPV-induced anal carcinomas as well as 40% of HPV-induced oropharyngeal 
carcinoma while in other anogenital areas is not well documented (153–155). The transgene construct 
is also flanked downstream by a 500-base-pair polyadenylated signal, crucial for mRNA maturation 
mechanisms and protection against enzymatic degradation (153) (Figure 14).  
It has been shown by different studies that the construct directed by the K14 promoter has a 
high-level expression in the different types of the squamous epithelia in transgenic mice, mimicking 
the unbalanced expression of the viral proteins in the onset of the human disease (156,157). Studies 
have also shown that the expression of the E6 and E7 oncoproteins is higher than the expression of 
E2 protein throughout all the epithelial layers, also mimicking what happens in humans after HPV 
integration (158). However, the total absence of E2, which usually happens after HPV integration in 
the human genome, doesn’t occur in this mouse model, being one of the current limitations.  
The K14-HPV16 mouse model allows the study of HPV-related lesions that develop at 
multiple epidermal and mucosal sites (152,153). Ear and chest skin are consistently affected by LSIL 
starting to appear phenotypically at four weeks old followed  by HSIL  as well as the development 
of anal papillomas (153). The K14-HPV16 mouse model mimics the human HPV-induced 
carcinogenesis once, the LSIL are histologically similar to the LGSL observed in humans, alongside, 
the HSIL lesions are similar to the HGSL in humans, the precursor lesion just before the development 
of carcinoma, that is characterized by an increased number of basaloid cells with irregular and 
hyperchromatic nucleus (159). The observed SSC in the K14-HPV16 mice and in HPV-related 
cancers in humans are also similar, with clusters of malignant epithelial cells surrounded by 
fibrovascular stroma (159). Studies also have shown that the immune activation and the consequent 
response against the expression of the viral oncoproteins in the K14-HPV16 mouse model lead to a 
chronic recruitment of inflammatory cells, which promote tumoral progression (160). Additionally, 
the K14-HPV16 is also characterized by cephalic alopecia together with an extensive hyperkeratosis 
and atrial erythema (Figure 15). Most of these lesions occur approximately at 20-30-week-old mice. 
A high mortality rate (> 50%) is observed after this period, while wild-type mice with FVB 
background usually live from 52 to 65 weeks.  
 
 
General Introduction 
 
 28 
 
 
 
 
 
 
 
Figure 15. Mus musculus.  a) and b) Wild-type mice, 30 weeks-old; c) and d) transgenic mice K14 HPV16, 30 weeks -
old. 
a) c) 
b) d) 
  
1.11. The Big Question:   
 
The diverse stromal microenvironment, epithelial background, secretions, microbiota, 
genetic expression and hormonal responses of the reproductive, anogenital and oropharyngeal 
anatomic regions may influence the behaviour of the HPV viral proteins (147). All these variants 
may also influence the response of the host immune system. 
Recent studies show that changes in the vaginal microbiota can increase the risk of HPV 
infection (161). On the other hand, an increase of HPV infection due to microbiota fluctuations in 
the anus and head and neck anatomic region still needs to be assessed.  Another example of a different 
response in HPV-infected organs is the human α-defensin 5 (HD5), that can block HPV infection 
since it can prevent the furin-mediated cleavage of the L2 protein, a crucial step for the virus entry 
in the cell (162) (Figure 7). This anti-viral protein is actively expressed in the vagina and vulva 
epithelia, however, poorly expressed in the cervix transformation zone, making this region more 
prone to HPV infections and therefore to the development of lesions (163). Additionally, hormones 
like oestrogen and progesterone can influence not only the immune system but also the HPV 
oncoproteins, mediating the development of lesions (164,165). 
Studies have shown that HPV may behave differently not only according to the gender it 
infects but also depending on the different anatomic locations in which the virus is present. For 
example,  the oropharyngeal region is particularly prone to HPV infection in comparison with the 
nearby oral cavity and larynx anatomic locations due to its architecture and lymphoepithelial 
background characterized by a disruptive basal cell layer that facilitates HPV viral access to the basal 
stem keratinocytes (147).  This anatomic region has an HPV viral load  80.000x higher than any other 
location in the head and neck anatomic regions (147). 
Understating these differences is crucial to develop novel and precise therapies that can have 
a different impact in the different anatomic sites of infection. There are still important and basic 
questions that still need to be answered regarding HPV infection. Do the HPV oncoproteins trigger 
a distinct grade of lesions on the different anatomic sites of infection? How does the different tissue 
stromal microenvironment of the uterine cervix, anal and oral epithelia allied with the HPV 
oncoproteins modulate tumour progression?  
 
 
  
Aims and scope 
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II. Aims and Scope 
 
The main goal of this study was to observe the influence of E6, E7 and E5 oncoproteins mRNA 
expression as well as the different lesions development on multiple anatomic sites usually infected 
by HPV that are characterized by the influence of gender, different epithelia backgrounds, genetic 
expression and tissue stromal microenvironments. 
The specific aims are to: 
I. Assess the expression of E6, E7 and E5 mRNA in female K14-HPV16 organs that are 
known to be affected by HPV in humans, namely the base of the tongue, anus and uterine 
cervix and correlate it with the histopathological features. 
II. Assess the expression of E6, E7 and E5 mRNA in male K14-HPV16 organs that are 
known to be affected by HPV in humans, namely the base of tongue, anus and penis and 
correlate it with the histopathological features. 
III. Assess the expression of E6, E7 and E5 mRNA in K14-HPV16 mouse bladder and 
compare it with the expression of the other studied organs. Correlate the mRNA 
expression with the histopathological characteristics.   
IV. Compare the expression of E6, E7 and E5 mRNA in K14-HPV16 male and female base 
of the tongue and anal samples.  
V. Correlate lesion progression with E6, E7 and E5 mRNA expression  
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III. Materials and methods  
 
3.1. K14-HPV16 transgenic mice 
 
The generation of the K14-HPV16 mice on an FVB/n background has been previously 
described by Arbeit and colleagues (153), comprising the entire early coding sequence of wild-type 
HPV16. The K14-HPV16 mice were kindly donated by Drs. Jeffery Arbeit and Douglas Hanahan, 
through the USA National Cancer Institute Mouse Repository. The animal experiments were 
approved by the University of Trás-os-Montes and Alto Douro Ethics Committee (10/2013) and the 
Portuguese Veterinary Directorate (0421(000/000/2014) and carried out at the University of Trás-os-
Montes and Alto Douro. The K14-HPV16 and the wild-type mice were maintained and bred 
according to the Portuguese (Portaria 1005/92 dated October the 23rd) and European (EU Directive 
2010/63/EU) legislation, with light-dark cycle (12h light / 12h dark), controlled temperature 
conditions between 20°-24°C, relative humidity (50 ± 10%), using corncob bedding. Food in form 
of pellets and water were provided ad libitum. Groups of four K14-HPV16 mice males and five K14-
HPV16 mice female were maintained in a type II cage with length, width, height: 26,5x20,5x14,5 
cm and with a floor space of approximately 545 cm2.  
 
3.2. Experimental design and sample collection  
 
Ten female and ten male K14-HPV16 mice, with 30-weeks-old, were randomized and 
blindly chosen to be used in the experiment. Several of the most common HPV-infected anatomic 
locations were collected. Ten samples of chest skin, the base of the tongue, anus, uterine cervix and 
bladder were collected from female K14-HPV16. Additionally, ten samples of chest skin, the base 
of the tongue (only 9 samples were collected), anus and penis samples were collected from male 
K14-HPV16 (Figure 16). Matched samples were used for E6, E7 and E5 mRNA quantification and 
histological analysis. All mice were sacrificed under a combination of ketamine and xylazine 
anaesthesia followed by intracardiac puncture and exsanguination, according to the established 
protocols of the Center for the Research and Technology of Agro-Environmental and Biological 
Sciences in the University of Trás-os-Montes and Alto Douro. All samples were collected into 
TripleXtractor isolation reagent (Grisp®), macerated and kept at −80 °C until further use.  
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3.3. Mouse Genotyping 
 
The K14-HPV16 mice were genotyped using a chest skin sample after organ collection. 
Wild-type mice were used as negative controls. DNA was extracted and purified using the GRS-
Genomic DNA Kit Broadrange (Grisp®), according to the manufacturer’s instructions. DNA 
concentration and purity were assessed by the NanoDrop®spectrophotometer v3.7 (Thermo 
Scientific, Wilmington DE, EUA). The HPV16-E7 and the reference β-globin genes were amplified 
using polymerase chain reaction (PCR) in order to confirm the integration of HPV DNA into the 
mouse genome by specific primers (Table 3). The 50 μL HPV16-E7 PCR reaction included 1x 
DREAM Taq buffer including 20mM MgCL2, 0,2 mM dNTP´s, 0,4 µM of each primer, 1U of DNA 
Taq polymerase and 200 ng/μL of genomic DNA. The amplification conditions were as follows: 
strand DNA denaturation at 95°C for three minutes, followed by 40 cycles at 94°C for 45 seconds, 
55°C for 45 seconds, 72°C for one minute and the final extension at 72°C for five minutes. The 
expected band size of 157 base pairs (bp) was then confirmed by electrophorese gel agarose 3%. The 
30 μL β-globin PCR reaction included 1x DREAM Taq buffer including 20mM MgCL2, 0,2 mM 
dNTP´s, 0,5 µM of each primer, 1U of DNA Taq polymerase and 200 ng/μL of genomic DNA. The 
amplification conditions were as follows: strand DNA denaturation at 94°C for three minutes, 
followed by 35 cycles at 94°C for 30 seconds, 60°C for 45 seconds, 72°C for 90 seconds and the 
final extension at 72°C for ten minutes. The expected band size of 494 base pairs (bp) was then 
confirmed by electrophorese gel agarose 1,5%.  
 
- Chest skin 
- Base of the tongue 
- Anus 
- Uterine cervix 
- Bladder 
HPV16 
(+/-)
 
HPV16 
(+/-)
 
- Chest skin 
- Base of the tongue 
- Anus 
- Penis 
 
Figure 16. Samples collection of chest skin, anus, base of the tongue, uterine cervix, bladder and penis in K14-HPV16 
mice  female and male. 
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Table 3. HPV16-E7 genotyping primer sequence. F - forward, R - reverse. 
 
 
 
 
 
 
3.4. Reference genes selection  
 
The genes used as references must fulfil several criteria. One of the most important principles 
is that their expression should not vary within the tissues or cells. Additionally, they should not be 
influenced by the experimental procedure  (166). Our reference gene expression stability analysis 
was based on two steps. We first identified the likely candidates for our experimental procedure, 
followed by the analysis of the stability of the chosen candidate genes by real-time polymerase chain 
reaction (RT-PCR). Taking this into consideration, we chose three widely used reference genes, the 
TATA-box binding protein (TBP), the hypoxanthine guanine phosphoribosyl transferase (HPRT) and 
beta-2-microglobulin (β2m), that showed to have the least variance within the different tissues in 
mice (167). Those three genes were then analysed by RT-PCR in the uterine cervix, the base of the 
tongue, anus, penis and bladder samples in order to choose the most stable reference gene to be used 
in subsequent tests.  The stability value was assessed by the NormFinder statistical program (168). 
This program requires at least 8 samples per experimental group and a minimum of three reference 
genes. The software analyses the inter- and intra-group variability, ranking them by their stability 
values, in which a lower value corresponds to a more stable gene. 
 
3.5. RNA extraction/purification and cDNA synthesis  
 
Total ribonucleic acid (RNA) was extracted from the tissue samples using the High Pure 
RNA Isolation Kit (Roche®) and treated with DNase I to avoid genomic DNA contamination. First 
strand synthesis of mRNA, complementary DNA (cDNA) was carried out by using the High Capacity 
cDNA Reverse Transcriptase kit (Applied Biosystems®). The reverse transcriptase reaction 
contained a total volume of 20μL with a 10μL master mix containing 1X RT buffer, 1X dNTP mix 
1X RT Random primers and 2,5 U of MultiScribeTM Reverse Transcriptase as well as 10μL of RNA 
sample.  
 
Gene  
 
Primer Sequence (5'->3') 
Amplicon 
size (bp) 
E7 F: GGAGGAGGATGAAATAGATGG 
R: GCCCATTAAGAGGTCTTCCAA 
 
157 
β-globin F: CCAATCTGCTCACACAGGATAGAGAGGGCAGG 
R: CCTTGAGGCTGTCCAAGTGATTCAGGCCATCG 
 
494 
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 The amplification conditions were as follows: 25°C for 10 minutes, 37°C for 120 minutes 
and a reverse transcriptase inactivation step at 85°C for five minutes. All reverse transcriptase 
reactions included a negative control. The reaction was performed in the Mycycler Thermal cycler 
(Bio-Rad).  
3.6. RT-PCR  
 
  After cDNA synthesis, real-time PCR analysis was conducted using the Fast SYBR Green 
Master Mix (Applied Biosystems®) and performed on the StepOne qPCR Real-Time PCR device 
(Applied Biosystems®). The RT-PCR reaction contained a total volume of 10μL, of which 5μL of 
the fast SYBR GREEN master mix, a primer concentration of 0,2 mM, 1μL of the respective cDNA 
and dH2O until the final volume. The cycling conditions were 95°C for 20 seconds, followed by 40 
cycles at 95°C for three seconds and 60°C-66°C (depending on the primer annealing temperature) 
for 30 seconds. An additional 95°C for 15 seconds, 60°C for one minute and 95°C for 15 seconds 
was used to confirm the amplification specificity of each reaction. Additional “No Template Control” 
(NTC) was used to ensure the absence of genomic DNA contamination. All qPCRs were run in 
duplicates and the average standard deviation within all samples and respective duplicates was 0,24. 
The PCR efficiencies of the mRNA targets were between 94%-100% with the consequent slope 
variation between 3,28-3,48. E6, E7 and E5 mRNA expression levels were normalized to the average 
expression of the two most suitable reference genes, TBP and HPRT, using specific primers, as 
described in Table 4 (169–171).  
 
Table 4. RT-PCR Primer sequences of E6, E7, E5, TBP, HPRT and β2m.  F - forward, R - reverse. 
 
Gene Primer sequence (5'->3') Main regulatory function 
Amplicon 
size (bp) 
E6 
F: GAGCGACCCAGAAAGTTACCAC 
R: ACCTCACGTCGCAGTAACTGTTG 
HPV viral oncoprotein 107 
E7 
F: ACCGGACAGAGCCCATTACAA 
R: GTGCCCATTAACAGGTCTTCC 
HPV viral oncoprotein 120 
E5 
F: CTTTGCTTTTGTGTGCTTTTGTGTG 
R: AAAGCGTGCATGTGTATGTATTAAA 
HPV viral oncoprotein 192 
TBP 
F: CAAACCCAGAATTGTTCTCCTT 
R: ATGTGGTCTTCCTGAATCCCT 
Transcription regulation of most 
genes 
131 
HPRT 
F:TGAAGAGCTACTGTAATGATCAGTCAAC 
R: AGCAAGCTTGCAACCTTAACCA 
Recycling of purines by the 
purine salvage pathway 
187 
β2m 
F: GGTCTTTCTGGTGCTTGTCTCA 
R: GTTCGGCTTCCCATTCTCC 
Component of the major 
histocompatibility complex class 
I 
103 
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3.7. Western blot Analysis  
 
The protein expression of E6 and E7 oncoproteins was evaluated by western blot. Proteins 
were isolated from the all mouse tissue samples using the TripleXtractor isolation reagent (Grisp®) 
and according to the manufacture instructions, containing protease inhibitors (HaltTM Protease & 
Phosphatase Inhibitor Cocktail; Thermo Scientific) at a specified concentration. Protein 
concentration was read using the DC Protein Assay (BIO-RAD) and then separated by SDS-PAGE 
(4-20% pre-cast gels) under reducing conditions. Proteins were then transferred by the Trans-Blot 
Turbo (BIO-RAD) onto PVDF membranes, blocked with 5% milk (BIO-RAD) in PBS-Tween 0.05% 
for one hour at room temperature. Primary monoclonal HPV16 E6/HPV18 E6, dilution 1:200 (Santa 
Cruz Biotechnology, sc-460); HPV16 E7, dilution 1:200 (Santa Cruz Biotechnology, sc-6981) and 
β-Actin, dilution 1:200 (Santa Cruz Biotechnology, sc-811178), were incubated for two hours at 
room temperature. After several washing steps, the membrane was incubated with secondary 
antibody m-IgGk BP-HRP, dilution 1:1000 (Santa Cruz Biotechnology, sc-516102) and revealed by 
chemiluminescence.   
 
 
3.8. Histological features  
 
 Samples for histological analysis were fixed in 10% neutral buffered formalin. The bladder 
was distended and fixed in situ, as previously described, to avoid histological artefacts (172). The 
fixed tissues were then dehydrated through graded alcohols and xylene and embedded in paraffin 
using an automatic STP 120 processor. The samples were histologically classified as 1) normal, if 
no alterations were observed in the epithelium, 2) LSIL, if characterized by a higher number of basal 
epithelium layers, however, without nuclear alterations and deformities (113). 3) HSIL, if a higher 
degree of disorganization and undifferentiated cells that extend beyond the lower third of the 
epithelium is observed, alongside with the loss of morphology as well as abnormal mitotic figures, 
namely the generally larger nucleus with two to three metaphysical groups, denser chromatin and 
cell membrane more prominent and distorted and 4) SCC, if a complete loss of differentiation and 
disorganization in almost all the epithelium is observed alongside with the invasion of the basal 
membrane (113).  The histopathological analysis was performed by an experienced pathologist, 
affiliated to the Molecular Oncology and Viral Pathology group, at the Portuguese Institute of 
Oncology (IPO-Porto) to the Center for the Research and Technology of Agro-Environmental and 
Biological Sciences, University of Trás-os-Montes and Alto Douro and to the Federal University of 
Maranhão, Brazil.   
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3.9. Statistical Analysis 
 
Statistical analysis was performed using the IBM SPSS Statistics for Windows (Version 
24.0). Kruskal-Wallis, Mann-Whitney and Livak methods were used to evaluate statistical 
differences in normalized relative expression of E6, E7 and E5 genes among the different tissue 
samples (base of the tongue, uterine cervix, anus, penis and bladder). The incidence of histological 
differences in the different studied groups was performed using the chi-squared test. Results were 
considered statistically significant when p values were lower than 0.05. 
 
 
 
 
 
 
 
 
 
 
  
Results 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Results 
 
 45 
IV. Results  
  
4.1. Mouse Genotyping  
 
The presence of the HPV16 construct was confirmed by the amplification of the E7 genomic 
region (157 bp amplicon) in the K14-HPV16 males and females used in this study (Figure 17). In 
the wild-type mice, used as negative controls, the HPV16 E7 amplicon was not observed. In both 
K14-HPV16 and wild-type mice the β-globin gene was amplified. Phenotypically, while the wild-
type mice did not show any epithelial lesions, all the mice in which the HPV16 was integrated into 
their genome presented several degrees of lesions in the chest skin and ear.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 17. K14-HPV16 and wild-type mice genotyping. The presence of the HPV16 DNA was assessed by amplifying 
the E7 regions concomitant with the β-globin reference gene expression. The expected 157 bp band can be observed in 
the K14-HPV16 mice while the expected 494 bp band can be observed in both K14-HPV16 and wild-type mice. 3% 
and 1,5% agarose gel respectively, 50 bp gene ladder.  MW – Molecular Weight  
494 bp 
bp bp 
MW MW 
157 bp 
bp bp 
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4.2. Reference genes selection 
 
The stability values of the TBP, HPRT and the β2m reference genes were assessed by RT-
PCR, using the Norm Finder statistical program (168).  This program uses a mathematical algorithm 
in order to identify the best reference gene based on a pairwise variation analysis, according to the 
intra- and inter-group variation. Lower values of average MNormFinder indicate a higher stability 
expression. The stability values of the candidate genes were: β2m= 0,278; TBP= 0,437 and HPRT= 
0,477 (Figure 18). However, the best combination of endogenous control genes is a combination of 
the average expression of TBP and HPRT, with a stability value of 0,221. The combined expression 
of TBP and HPRT was consequently used as reference genes in this study. The stability values of the 
candidate genes were similar with the ones presented in previous studies (167). 
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Figure 18. Normfinder analysis of the β2m, TBP, HPRT stability values. 
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4.3.  Aim I 
 
4.3.1.  E6, E7 and E5 mRNA expression in K14-HPV16 
female mice base of the tongue, anus and uterine 
cervix  
 
Being the uterine cervix, the base of the tongue and the anus the most affected anatomic sites 
by HPV in women, we compared the E6, E7 and E5 oncogenic mRNA expression in the K14-HPV16 
female mice tissue samples (Figure 19). The expression of the E6 oncogenic mRNA was similar 
between the base of the tongue, anus and uterine cervix samples (p=0,155). Additionally, the 
expression of the E7 and E5 mRNAs showed also no significant statistical difference between the 
base of the tongue and anal samples (p=0,199 and p=0,386, respectively).  However, the uterine 
cervix was the anatomic location where more differences were found. The expression of the uterine 
cervix E7 mRNA was lower compared with the E7 mRNA expression in the base of the tongue and 
anal samples (p=0,016 and p=0,017 respectively). Alongside, the uterine cervix E5 mRNA 
expression was also lower when compared with the E5 mRNA expression of the anal samples 
(p=0,007) but with no statistically difference with the E5 mRNA expression in the base of the tongue 
(p=0,110). We can also observe a different expression pattern of E6, E7 and E5 mRNAs in the three, 
being the E6 mRNA the most expressed one followed by E7 and E5 (E6>E7>E5), (p<0,001). 
 
 
 
 
Figure19. 
Normalized 
relative expression 
(-ΔCt) of E6, E7 
and E5 in K14-
HPV16 female 
mice base of 
tongue, anus and 
uterine cervix.  
Base of the tongue  Anus Uterine cervix 
 **   **   **  
 ** p<0.01, n=10; o = Mild outlier; * = Extreme Outlier  
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4.3.2. Histopathology of K14-HPV16 female mice base 
of the tongue, anus and uterine cervix 
   
 
 
Regarding the histopathological features, 100% (10/10) of the uterine cervix samples showed 
normal epithelium with no associated lesions. Concerning, the anal samples, 10% (1/10) were 
classified also as normal epithelium without any notorious cellular alterations but the remaining 90% 
(9/10) developed LSIL. In the base of the tongue samples, 60% (6/10) were also classified as LSIL 
but 40% (4/10) of the samples developed more advance lesions, namely 20% (2/10) being classified 
as HSIL and other 20% (2/10) invasive SCC. The penetrance of the female base of the tongue, anus 
and uterine cervix lesions are described in Table 5. 
 
Table 5. Spectrum of HPV-induced lesions in K14-HPV16 females’ base of the tongue, anus and uterine cervix.  
 
Images of the base of tongue normal tissue (Figure 20 a), LSIL (Figure 20 b), HSIL (Figure 
20 c) and SCC (Figure 20 d), are displayed below. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Age 
(weeks) 
Organs Normal LSIL HSIL Invasive SCC 
 
 
Female 
30 Base of the 
tongue 
---- 60% 
6/10 
20% 
2/10 
20% 
2/10 
30 Anus 10% 
1/10 
90% 
9/10 
---- ---- 
30 Uterine 
cervix 
100% 
10/10 
----  ---- ---- 
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Furthermore, images of the anal normal tissue (Figure 21 a) and LSIL (Figure 21 b) are also 
displayed in the following figures.  
 
 
 
 
 
 
 
 
 
 
 
 
a) 
d) 
Figure 20). Histological analysis of mice wild-type and K14-HPV16 base of the tongue samples. Hematoxylin 
and eosin stain (H&E), 200x. a) wild-type mice, showing normal base of the tongue epithelia, b) K14-HPV16 
mice with LSIL in the base of the tongue, c) K14-HPV16 mice with base of the tongue HSIL epithelia and d) 
K14-HPV16 mice with base of the tongue invasive SCC. 
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Additionally, an image of the uterine cervix normal epithelia is also displayed below (Figure 22) 
 
b) 
Figure 21. Histological analysis of wild-type and K14-HPV16 mice anal samples H&E, 200x. a) Wild-type mice, 
showing normal anal epithelia.  b) K14-HPV16 mice with anal LSIL. 
Figure 22. Histological analysis of K14-HPV16 mice uterine cervix samples, showing normal epithelium. H&E, 100x 
Keratin  
Rectum epithelia  
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4.4. Aim II 
 
4.4.1. E6, E7 and E5 mRNA expression in K14-HPV16 
male mice base of the tongue, anus and penis 
 
We then quantified E6, E7 and E5 mRNA expression in the K14-HPV16 male base of the 
tongue, anus and penis samples, the most common HPV-infected anatomic locations in males.  Even 
though the mRNA expression of the three mRNA oncoproteins showed to be less precise when 
compared with the female samples, the base of the tongue, anus and penis showed similar expression 
of E6, E7 and E5 mRNA, with no statistically differences observed (p=0,125; p=0,547; p=0,490, 
respectively) (Figure 23). Different expression patterns of E6, E7 and E5 mRNAs are also observed 
more evidently in the K14-HPV16 base of the tongue (p=0,047) and anus (p=0,001), in comparison 
with the penile samples (p=0,290).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 23. Normalized relative expression (-ΔCt) of E6, E7 and E5 in K14-HPV16 male mice base of tongue, anus and 
penis.    
Base of the tongue  Penis Anus 
 **   *  
 * p<0.05, n=10 
** p<0.01, n=10 
o = Mild outlier  
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4.4.2. Histopathology of K14-HPV16 male mice base of 
the tongue, anus and penis 
 
 
Histologically and similarly with the female samples, the K14-HPV16 male base of the 
tongue developed the most advanced lesions. 11% (1/9) of the base of the tongue samples were 
classified as normal epithelium, 55% (5/9) developed LSIL, 22% (2/9) developed HSIL and 11% 
(1/9) developed invasive SCC. Regarding the male K14-HPV16 anal samples, 100% (10/10) of the 
lesions were LSIL. Additionally, the most diagnosed lesion in penile samples was LSIL (80%) (8/10), 
whereas 20% (2/10) developed HSIL. The penetrance of lesions of the K14-HPV16 male mice base 
of the tongue, anus and penis is described in Table 6. 
 
Table 6. Spectrum of HPV-induced lesions in K14-HPV16 males’ base of the tongue, anus and penis. 
 
Images of the normal penile tissue (Figure 24 a), penile LSIL epithelia (Figure 24 b) and penile 
HSIL epithelia (Figure 24 c), are shown in the figures below.   
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---- 
66% 
6/9 
22% 
2/9 
11% 
1/9 
30 Anus ---- 
100% 
10/10 
---- ---- 
30 Penis ---- 
80% 
8/10 
20% 
2/10 
---- 
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Figure 24. Histological analysis of wild-type and K14-HPV16 mice penile samples H&E, 200x. a) Wild-type mice, 
showing normal penis epithelia, b) K14-HPV16 mice with penis LSIL. c) K14-HPV16 mice with penis epithelial HSIL  
b) 
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4.5. Aim III 
 
4.5.1. E6, E7 and E5 mRNA expression in K14-HPV16 
mice bladder  
 
 Posteriorly, we measured the levels of E6, E7 and E5 in the bladder samples (Figure 25). 
Due to the controversial role of HPV in bladder carcinogenesis, we have performed this analysis in 
the samples from one gender only, namely in the female mice and compared its expression with the 
samples from the base of tongue, anus and uterine cervix. Future studies, englobing the bladder of 
the K14-HPV16 male mice, will be performed. We found that the E6 and E7 transgenic expression 
was very low, almost residual when comparing with the oncogenic mRNA expression from the base 
of the tongue, anus and uterine cervix (p<0,01) (Figure 25). In bladder tissues, we did not detect E6 
and E7 mRNA expression in four and five samples respectively. Alongside, no detectable E5 mRNA 
expression was observed in all the bladder samples. In the bladder, as similar as in other organs, there 
is also a different pattern expression between E6 and E7 mRNA expression (p=0,045). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 25. Normalized relative expression (-ΔCt) of E6, E7 and E5 in K14-HPV16 female base of tongue, anus and 
bladder 
Base of the tongue Bladder Uterine cervix  Anus 
** p<0.05, n=10, o = Mild outlier, *= Extreme outlier   
 
 
** 
Base of the tongue Anus Uterine cervix  Bladder 
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4.5.2. Histopathology of K14-HPV16 mice bladder  
 
 Histologically, all K14-HPV16 bladder tissue was classified as normal, with no notorious 
cellular alterations (Figure 26). The penetrance of bladder lesions is described in Table 7 
 
Table 7. Spectrum of HPV-induced lesions in the K14-HPV16 bladder samples. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Female 
Age (Weeks) Organs Normal LSIL HSIL Carcinoma in 
situ 
30 bladder 10/10 
100% 
---- ---- ---- 
Figure 26. Histological analysis of K14-HPV16 mice bladder samples H&E, 200x. Normal bladder epithelia. 
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4.6. Aim IV 
 
4.6.1. E6, E7 and E5 mRNA expression in K14-HPV16 
male and female base of the tongue  
 
The next step was to observe if there was a difference in the E6, E7 and E5 mRNA expression 
between genders, taking into consideration possible variations in physiological, immune and 
hormonal backgrounds. We observed a higher E6 mRNA transgene expression, namely six times 
higher, in the female base of the tongue when compared with the males’ base of the tongue (p=0,027). 
However, E7 and E5 mRNA expression were similar between genders (p=0,806 and p=0,441 
respectively) (Figure 27).  
 
 
 
Histologically, the K14-HPV16 female mice base of tongue developed approximately 50% 
more invasive SCC when compared with the K14-HPV16 male mice base of the tongue (20% versus 
11%). The penetrance of HPV-induced lesions in the K14-HPV16 base of the tongue male and female 
lesions is described in Table 8. 
Figure 27. Normalized relative expression (-ΔCt) of E6, E7 and E5 in K14-HPV16 female and male base of the 
tongue. 
Base of the tongue female  Base of the tongue male  
o = Mild outlier 
*= Extreme outlier   
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Table 8. Spectrum of HPV-induced lesions in the K14-HPV16 base of the tongue male and female. 
 
4.6.2.  E6, E7 and E5 mRNA expression in K14-HPV16 
male and female anus  
 
We also compared the E6, E7 and E5 mRNA expression between the K14-HPV16 female 
and male mice anal samples. We found that all the three transgene mRNAs were expressed similarly 
in both genders, with no statistically significant differences observed (p=0,935; p=0,072 and p=0,627 
respectively) (Figure 28).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Female  
 
Male 
Age 
(Weeks) 
Organs Normal LSIL HSIL Invasive SCC 
30 
Base of the 
tongue 
---- 
66% 
6/9 
22% 
2/9 
11% 
1/9 
30 
Base of the 
tongue 
---- 60% 
6/10 
20% 
2/10 
20% 
2/10 
Figure 28. Normalized relative expression (-ΔCt) of E6, E7 and E5 in female and male anal samples.  
 
Anus female  Anus male  
* = Extreme outlier   
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Histologically, the only lesions observed in the anal samples of both genders were classified as LSIL 
with very similar incidences (90% female and 100% male LSIL anal lesions). The penetrance of 
HPV-induced lesions in the K14-HPV16 base of the tongue male and female lesions is described in 
Table 9. 
 
Table 9. Spectrum of HPV-induced lesions in the K14-HPV16 anus male and female. 
 
 
 
4.7. Aim V 
 
4.7.1. Correlation between lesion progression with E6, 
E7 and E5 mRNA expression 
 
Our next step was to observe if there was any correlation between the grade of the lesions 
(LSIL and HSIL/SCC) and the expression of the E6, E7 and E5 mRNAs. This analysis was only 
performed for the base of the tongue samples, in the K14-HPV16 female mice, once in this tissue, 
all the cascade carcinogenic lesions were present. Additionally, the HSIL and SCC lesions were 
inserted in the same group due to the fact that HSIL is the immediate lesion right before the 
development of SCC. The mRNA E6, E7 and E5 expression was similar between the LSIL and the 
HSIL/SCC (p=0,831; p=0,670 and p=0,522 respectively). The results showed that the severity of 
lesions does not necessarily correlate with a different expression of the E6, E7 and E5 mRNAs 
(Figure 29). 
 
 
 
 
 
 
 
 
 
 
 
 
Female  
 
Male 
Age 
(Weeks) 
Organs Normal LSIL HSIL Invasive SCC 
30 
Anus  10% 
1/10 
90% 
9/10 
---- ---- 
30 Anus ---- 
100% 
10/10 
---- ---- 
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4.8. Western blot analysis  
 
The western blot results were not available in time for this dissertation. The secondary 
antibody bound unspecifically to all samples at a molecular weight of approximately 25 kDa, which 
masked the protein signal of the E6 and E7 oncoprotein which was 23 kDa and 20 kDa, respectively. 
We then have tried the Protein G PLUS-Agarose Reagent (Santa Cruz Biotecnhology sc-2002) in 
order to clear the lysates and reduce the unspecific signal, however with no success. We have also 
tried several different washing steps, secondary incubation time, substrate incubation time, but none 
with success. The next step will be to use a conjugated primary antibody, which if specific enough 
will allow the visualisation of E6 and E7 oncoproteins.    
 
 
Figure 29. Normalized relative expression (-ΔCt) of E6, E7 and E5 in female base of the tongue LSIL and HSIL/SCC. 
* = Extreme outlier   
 
 
E6  E7 E5  
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* = Extreme outlier   
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V. Discussion 
 
5.1. E6, E7 and E5 mRNA expression and 
histopathological features  
 
Infection by HPV is considered a huge public health burden afflicting millions of people and 
being one of the main etiological factors for the development of cancer (1). It is responsible for the 
development of lesions that can progress to cancer in the reproductive, anogenital and oral anatomic 
sites (2). Even though the carcinogenic cascade of the cervical cancer is widely studied and 
understood, in the other anatomic locations infected by HPV, it is still limited. Differences in the 
natural history of HPV as well diverse epithelia backgrounds and tissue stromal microenvironments 
may play a key role in the behaviour of the HPV oncoproteins, which can potentiate different 
temporal, physiological and molecular actions in the different anatomic sites of infection. 
Understanding these differences can be crucial not only for a better knowledge of the HPV-related 
carcinogenic steps but also for the development of novel and more precise therapies. Nevertheless, 
there are main gasps of knowledge when it comes to the specific tissue’s stromal microenvironment 
and its influence on tumour development, especially in the HPV induced-OPSCC where there is a 
lack of precancerous lesions characterization allied to the difficulty of having samples.  
This study allows a first insight of the likely different behaviour of the HPV oncoproteins in 
the different anatomic sites of infection resulting in the development of a different grade of lesions 
in the different anatomic sites of infection. Alongside, this is the first study of the expression profile 
of the malignant oncoproteins E6, E7 and E5 in the several anatomic sites of HPV infection in the 
K14-HPV16 mouse model, that mimics the carcinogenic cascade of HPV-related cancers in humans.  
Even though the expression of E6, E7 and E5 were similar in the base of the tongue and anus 
in both genders, the base of the tongue tissues developed more advanced lesions, namely HSIL and 
SCC, compared with the anus, where LSIL were mainly observed. Alongside, in the penile tissue 
samples, HSIL lesions were also observed, even though the transgene HPV viral mRNA expression 
was similar to the remaining male tissue samples. Expectably, no HPV-related lesions were observed 
in the uterine cervix and in the bladder samples. Overall, we verify a huge difference in the 
oncoproteins regulation in the different tissues. Therefore, other factors apart from the HPV mRNA 
transgene expression must be present in the different tissues, mediating the development of the 
different lesions observed. Some hypothesis apart from the pro-tumoral chronic inflammation 
seemed also to be important namely a differential expression of microRNA´s and hormonal 
receptors.   
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5.1.1. Implications of the anatomic site 
microenvironment  
 
5.1.1.1. Base of the tongue samples 
The oropharyngeal region, which comprises the base of the tongue, the soft palate, the side 
and back walls of the throat and the tonsils is characterized by a vast lymphoepithelial 
microenvironment, where a continuous spreading lymphocyte infiltrate containing 
immunomodulating agents is continuously produced (147,173). Even though the lymphoepithelial 
tissue is characterized by a fast counteraction of the immune system, functioning as a protective 
barrier against infection, when viral load is intense and continuous allied with the capability of the 
impairment of the HPV oncoproteins E6, E7 and E5 onto the immune system regulatory mechanisms, 
as it happens in the K14-HPV16 mouse model, it will lead to an unresolved inflammation as well as 
pro-tumoral phenotype transformation process which will eventually promote the a decay and 
decrease function of the immune system and a consequent progression of the HPV-related lesions 
into malignant tumours (160,174).  Consequently, macrophages, mast cells, neutrophils and other 
innate immune cells may be chronically recruited in the already near lymphoepithelial tissues, 
supplying cytokines, chemokines, reactive oxygen species (ROS), growth factors and other 
biomolecules where together with the viral oncoproteins, can modulate a faster malignant 
progression by promoting a pro-tumoral phenotype of the immune cell components and increasing 
the occurrence of genetic and epigenetic events that are key factors for malignant progression (175–
178). Additionally, studies have shown that  E6 and E7 oncoproteins from HPV16 increase the 
transcription activity of MMP and consequently the malignancy of the HPV-related lesions, once 
these molecules are associated with an increase angiogenesis mechanisms and consequently lesion 
progression (179). Additionally, the results showed that the severity of the lesions were not 
influenced by a higher or lower oncogenic mRNA expression (Figure 29), reinforcing the existence 
of other internal co-factors for the development of lesions. In HPV-positive oropharyngeal cancers 
in humans, there are still no established co-factors identified since these types of cancers tend to 
appear in younger people that do not smoke or drink (180). However, they may be enhanced by some 
external factors such as food components (Rui M. Gil da Costa, Tiago Neto, Diogo Estêvão et al. 
Ptaquiloside from bracken (Pteridium spp.) promotes oral carcinogenesis initiated by HPV16 in 
transgenic mice. Life Sciences (submitted). 
Our results suggest that in the base of the tongue, HPV oncoproteins, together with the 
oropharyngeal specific microenvironment, where a chronic recruitment of inflammatory cells may 
happen is a sufficient cause for the development of SCC.  
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5.1.1.2. Anal samples 
In the anal samples either in K14-HPV16 male and female, the only type of lesions observed 
was LGSL. However, even though the expression of the HPV oncoproteins was enough to induce 
the first stage in the carcinogenic cascade, the time-line used in this study (30 weeks) was not 
sufficient to promote more advance lesions in a way of promoting additional molecular alterations 
for tumour progression, therefore, a longer study would be necessary to evaluate if HPV alone could 
promote the development of more advance lesions. Additionally, a decrease of immune pro-tumoral 
cells infiltration in the anal region compared with the base of the tongue could lead to a failure of 
lesion progression from LSIL.  Furthermore, could also be interesting to study if the influence of 
other co-factors could reduce the time in which we would observe more advance lesions. In humans, 
several factors for the development of anal carcinomas have been identified. Apart from HPV, HIV 
infections, multiple sex partners, men who have sex with men, smoking and a consequent lower 
immunity seem to play important roles in the development of anal cancer (120,137).  
5.1.1.3. Uterine cervix samples 
In the uterine cervix, we only observed normal epithelium, with no associated lesions. The 
expression “per se” of the HPV oncoproteins appeared to be insufficient to induce the development 
of lesions in the uterine cervix.   However, it is known that female K14-HPV16 mice, when exposed 
chronically to oestrogen, namely 17β-oestradiol, start to develop benign proliferation, ending in 
uterine cervix SCC in 100% of the treated mice (164). Another study led by Auborn and colleagues 
showed that the administration of an anti-oestrogen compound (indole-3-carbinol) could hamper 
uterine carcinogenesis (181) . Furthermore, this compound also seemed to reduce other highly 
advanced lesions commonly found in the chest skin and ear of the K14-HPV16 mice. It is, therefore, 
well established that HPV persistent infection is a necessary but not sufficient cause for the 
development of cervical cancer. The powerful role of hormones as potent and necessary co-factors 
that act in synergy with the HPV oncoproteins promote the malignancy development by altering the 
stromal tissue microenvironment in the uterine cervix which may explain why no lesions were 
observed with the action of the HPV oncoproteins alone (118,182).  
5.1.1.4. Penile samples  
In the penile tissue, we reported the development of more advanced lesions, namely HSIL. 
Although HSIL is the event immediately before SCC, we have not observed this type of lesion in 
any of the penile samples. We speculate that more time would be necessary for the development of 
penile cancer in K14-HPV16 male mice. When dissecting the male samples, we could observe large 
and inflamed inguinal lymph nodes close to the penis (Figure not shown).  
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As a hypothesis, we think that the specific microenvironment found near the penis, together 
with the viral oncoproteins could influence the progression of more advance lesions from LSIL to 
HSIL, similarly but not with the same influence and clearly not at the same time  (30 weeks) as it 
might happen in the base of the tongue (183). Alongside, HPV-induced penile carcinogenesis may 
be enhanced by external carcinogenic compounds that are commonly found in cigarettes and can 
promote a faster and a more aggressive development of carcinogenic lesions. (Rui M. Gil da Costa, 
Diogo Estêvão et al. HPV16 induces penile intraepithelial neoplasia and penile squamous cell 
carcinoma in transgenic mice: a mouse model for penile cancer (paper under preparation) ). 
5.1.1.5. Bladder samples  
 
Our results showed that in K14-HPV16 mice bladder tissue, the expression of E6 and E7 
mRNA was residual and not present in all the samples. Alongside, there is no expression of E5 
mRNA. Furthermore, the bladder histology was normal with no apparent lesions identified. HPV 
etiological role in the urinary tract, particularly in the bladder, has always been controversial and 
inconclusive (184). Studies in which HPV was found in bladder cancer showed a wide range of 
prevalence, from 0-80%. Actually, some researchers speculate contamination issues when HPV is 
detected in bladder tissues, due to HPV almost ubiquitous presence and easy contamination, leading 
to false positive results (185). Epithelium constraints of the bladder that is formed by the basal, 
intermediate and superficial (umbrella) cells allied to the non-viremic characteristic of HPV, can 
influence the non-successful HPV infection in the urinary tract (12). The bladder is characterized by 
a transitional cell epithelium, not favourable to HPV infection that needs a complete stratified 
epithelium to its life cycle replication (12). However, the residual mRNA expression of E6 and E7 
in the bladder samples is explained by the recently discovered existence of a very small subset of 
basal cells that express K14 (186). (Rui M. Gil da Costa, Tiago Neto, Diogo Estêvão et al. 
Ptaquiloside from bracken (Pteridium spp.) promotes oral carcinogenesis initiated by HPV16 in 
transgenic mice. Life Sciences (submitted). 
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A summary of the different temporal lesions developed in the K14-HPV16 studies tissues 
exposed to chronic expression of HPV oncoproteins is shown in Figure 30.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Bladder 
Figure 30. Carcinogenic cascade of HPV-induced lesions in the K14-HPV16 base of the tongue, penis, anus, 
uterine cervix and bladder.  
Base of  
the tongue 
Penis 
Anus 
Normal  LSIL HSIL SCC 
30 weeks  
Uterine 
cervix  
Discussion 
 
 66 
5.1.2. Implications of the gender: Females versus males 
 
This study revealed that in the base of the tongue there is a higher incidence of SCC in 
females in comparison to males (20% vs 10% respectively). Therefore, the K14-HPV16 female base 
of the tongue appears to be more susceptible to the progression of the malignant lesions.  This 
susceptibility may be explained by circulating levels of steroid sex hormones, namely oestradiol and 
glucocorticoids, that can influence the development of such lesions in an already prone anatomic 
regions for the development of high advance lesions (187). The steroid sex hormones are also known 
to enhance the expression and behaviour of the viral oncoproteins E6, leading to a higher degradation 
of p53 protein and consequently inducing a more prominent carcinogenic cascade (188).  
 
5.1.3. Expression profile of E6, E7 and E5 mRNA 
 
Interestingly, in our study we found an almost homogenous expression profile of the E6, E7 
and E5 mRNA reported in the studied tissues (E6>E7>E5). 
Several mechanisms can influence the gene expression, justifying these results (189). 
Mechanisms of alternative splicing, polyadenylation and methylation towards the transgene cassette 
can interfere and change the genetic expression (189). Most mammalian mRNA undergoes 
alternative splicing (190). Alternative splicing is the process by which several mature mRNA 
sequences and protein isoforms can be achieved from the same coding gene (190). The HPV genome 
is polycistronic, encoding from one mature mRNA two or more proteins. Alternative splicing 
processes are used in order to generate different HPV mRNAs, having alternative transcription ends 
which can justify the cascade expression of the transgenes mRNAs (191,192).  Studies have shown 
that there are intensive alternative splicing processes in the HPV16 genomic E6 and E7 regions, 
creating several isoforms, that have been shown to be implicated in the carcinogenesis processes of 
the HPV-related cancers (193,194). Alongside, E2 protein can interact with the spliceosome 
molecules, increasing the alternative splicing rate (195).  
It is also known that in polycistronic mRNA, the first ORF, being this the case of E6 mRNA 
in the transgene cassette (Figure 14), can be translated more efficiently when intercistronic distances 
are short (196). Additionally, the E6 mRNA is also found to be the most abundant transcript in the 
carcinogenesis lesions of cervical cancer (196). This hypothesis can justify the existence of a more 
abundant E6 mRNA transgene transcript in comparison with the E7 and E5 transcripts (E6>E7>E5).  
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Other studies refer that the splicing mechanisms can be regulated by the epidermal growth 
factor (EGF) (196). Since E5 can promote a higher EFG activation and the K14-HPV16 is 
characterized by a continuous expression of this viral protein, this could lead to an increment of the 
alternative splicing mechanisms, leading to a higher transcription of E6 isoforms (73,197). 
Chromatin conformation and RNA secondary structure also play a role in determining the 
efficiency of alternative splicing and which exons are spliced out or retained (190). Additionally, the 
promoter used in order to initiate the transcription can also influence the splicing mechanisms (198). 
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VI. Concluding remarks and future perspectives  
 
HPV-related cancers are still a major worldwide health concern. It is, therefore, crucial to 
fully understand the oncogenic mechanisms involved in their development.  The K14-HPV16 mouse 
model has an enormous potential for unravelling the HPV-related carcinogenesis steps. This 
knowledge may allow the development of target therapies against HPV-derived cancers, mainly 
anogenital and head and neck cancers that are globally increasing. This study enlightens the proof of 
concept of an earlier and less-external-cofactor dependent carcinogenesis induced by HPV in 
oropharyngeal cancers in comparison with other anatomic localizations namely the uterine cervix, 
the anus and even the penis, where HPV alone and taking in consideration the 30-week period of the 
experiment is therefore necessary but seems not to be sufficient to induce squamous cell carcinomas. 
This work may also recognize the stromal microenvironment especially in the oropharyngeal region 
as a co-factor for the development of HPV related lesions. We also conclude that due to the almost 
inexistent expression of E6, E7 and E5 mRNA in the bladder, allied with its transitional epithelium, 
it is unlikely that HPV induces bladder carcinoma. Furthermore, for the first time, the K14-HPV16 
mouse model seems to be useful for the study of HPV-induced oropharyngeal cancers once it 
develops different grades of lesions led by the molecular action of the HPV alone.  
Future studies should focus on understating the communication between the different tissue 
stromal microenvironments of the different HPV anatomic sites of infection and the role of the HPV 
oncoproteins as well as the quantification, in the different tissues of inflammatory cells that are 
known to be a switch from pre-cancerous lesions to malignant ones. Previous studies have shown 
that in the K14-HPV16 mouse model, the inflammatory cell profile was different in the epithelial 
skin cancer compared with the cervical cancer, once more emphasising the despair genetic, hormonal 
and microenvironmental regulation that happen in the different tissues even though influenced by 
the expression of the same oncogenes (199,200).  Furthermore, it would be important to investigate 
the influence of external hormonal and carcinogenic compounds in the development of the lesions in 
the several anatomic locations of HPV carcinogenesis and its effect on the already pre-existing ones.   
The oncogenic viral proteins E6, E7 and E5, being highly expressed in HPV-related lesions, 
are consequently one of the best targets for therapeutic applications, once they are the main drivers 
of high-grade lesions´ that eventually progress to cancer. While conventional therapeutic approaches 
such as surgery, chemotherapy and radiotherapy are the most commonly used treatment for cancer 
patients, tumour resistance and recurrence are frequent problems, decreasing the survival and quality 
of life of patients. Therefore, there is a sustained need for new and more effective cancer therapeutics.  
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More recently, the clustered regularly interspaced short palindromic repeats-associated 
protein 9, (CRISPR-Cas9), has emerged as a powerful genome-editing tool with boundless 
applications namely in mutation correction, inactivation of oncogenes and activation of tumour 
suppressor genes (201). In the future, a promising approach would be to use this technique to 
permanently disrupt the E6, E7 and E5 genes from the transgenic K14-HPV16 mouse genome.  In 
another mouse model, this removal has shown to decrease p53 ubiquitination, as well as to increase 
cell cycle arrest, increasing the animals´ lifespan (202–204). Therefore, CRISPR-Cas9 seems to be 
a promising technology with therapeutic applications in HPV-related cancers  (201). Estêvão D. et 
al. CRISPR-Cas9 therapies in experimental mouse models of cancer. Future Oncology. 2018 July. 
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8.1. Median, Q1 and Q3 values of E6, E7 and E5 mRNA 
expression  
 
 
 
 
 
 
 
 
 
 
E6_base 
of the 
tongue 
 
E7_base 
of the 
tongue 
 
E5_base 
of the 
tongue 
 
E6_anus 
 
E7_anus 
 
E5_anus 
 
E6_uterine 
cervix 
 
E7_uterine 
cervix 
 
E5_uterine 
cervix 
Median 5,145 2,095 -0,955 4,135 2,520 -0,430 1,795 -2,440 -4,940 
Q1 4,086 1,448 -1,308 3,362 1,558 -1,380 0,705 -3,998 -6,103 
Q3 5,658 2,485 -0,722 5,183 3,070 0,215 5,615 1,943 -0,528 
 
E6_base of 
the tongue 
E7_base of 
the tongue 
E5_base of 
the tongue 
E6_anus E7_anus E5_anus E6_penis E7_penis E5_penis 
Median 2,560 1,900 -0,720 4,200 1,550 -0,130 1,870 1,570 -1,120 
Q1 1,350 0,195 -1,755 2,245 -0,865 -2,185 0,550 -0,170 -2,708 
Q3 4,675 4,320 2,080 5,450 1,985 0,760 2,855 2,655 0,352 
 
E6_base 
of the 
tongue 
E7_base 
of the 
tongue 
E5_base 
of the 
tongue 
E6_anus E7_anus E5_anus E6_uterine 
cervix 
E7_uterine 
cervix 
E5_uterine 
cervix 
E6_bladder E7_bladder 
Median 5,145 2,095 -0,955 4,135 2,520 -0,430 1,795 -2,440 -4,940 -6,650 -9,150 
Q1 4,086 1,448 -1,308 3,362 1,558 -1,380 0,705 -3,998 -6,103 -8,120 -10,30 
Q3 5,658 2,485 -0,722 5,183 3,070 0,215 5,615 1m943 0,528 -4,83 -8,30 
Table 12. E6, E7 and E5 values of Median, Q1 and Q3 in K14-HPV16 female base of tongue, anus and bladder 
Table 10. E6, E7 and E5 values of Median, Quartile 1 (Q1) and Quartile 3 (Q3) in K14-HPV16 female mice base of 
tongue, anus and uterine cervix.  
Table 11. E6, E7 and E5 values of Median, Q1 and Q3 in K14-HPV16 male mice base of tongue, anus and penis.    
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 E6_base of the 
tongue female 
E7_base of the 
tongue female 
E5_base of the 
tongue female 
E6_base of 
the tongue 
male 
E7_base of 
the tongue 
male 
E5_base of 
the tongue 
male 
Median 5,145 2,095 -0,955 2,560 1,900 -0,720 
Q1 4,086 1,448 -1,308 1,350 0,195 -1,755 
Q3 5,658 2,485 -0,722 4,675 4,320 2,080 
 E6_anus 
female 
E7_anus 
female 
E5_anus 
female 
E6_anus 
male 
E7_anus 
male 
E5_anus 
male 
Median 4,135 2,520 -0,430 4,200 1,550 -0,130 
Q1 3,362 1,558 -1,380 2,245 -0,865 -2,185 
Q3 5,183 3,070 0,215 5,450 1,985 0,760 
 E6_LSIL E7_LSIL E5_LSIL E6_HSIL/SCC E7_HSIL_SCC E5_HSIL_SCC 
Median 5,140 2,060 -0,900 5,170 2,210 -1,115 
Q1 2,245 0,590 -1,745 4,258 1,323 -2,275 
Q3 5,450 2,430 0,330 5,873 2,535 0,7500 
Table 13. E6, E7 and E5 values of Median, Q1 and Q3 in K14-HPV16 female and male base of the tongue. 
Table 14. E6, E7 and E5 values of Median, Q1 and Q3 in female and male anal samples.  
 
Table 15.  E6, E7 and E5 Values of Median, Q1 and Q3 in female base of the tongue LSIL and HSIL/ SCC 
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8.2. Oral communication in the EUROGIN 2018, Lisbon, 
Portugal 
 
K14-HPV16 MOUSE MODEL: A JOURNEY TOWARDS EARLY HPV-
INDUCED HEAD AND NECK VS ANAL AND UTERINE 
CARCINOGENESIS   
 
Diogo Estêvão a,b,, Verónica Filipa Mestre e,f, Beatriz Medeiros-Fonseca e,f,, Francisca Diasa, Margarida 
M.S.M. Bastos d, ,Paula A. Oliveira e,f,, Natália Rios Costa a, Rui M. Gil da Costa a, d, e , Rui Medeiros a, b, c, g 
 
a Molecular Oncology and Viral Pathology Group, IPO-Porto Research Center (CI-IPOP), Portuguese 
Institute of Oncology of Porto (IPO-Porto), Rua Dr. António Bernardino de Almeida, 4200-072 
Porto, Portugal 
b FMUP, Faculty of Medicine, University of Porto, Alameda Professor Hernâni Monteiro, 4200-319 Porto, 
Portugal 
c LPCC, Research Department Portuguese League Against Cancer (Liga Portuguesa Contra o Cancro—
Núcleo Regional do Norte), Estrada Interior da Circunvalação, no. 6657, 4200-177 Porto, 
Portugal 
d LEPABE, Faculty of Engineering, University of Porto, Rua Dr. Roberto Frias s/n, 4200-465 Porto, Portugal 
e Center for the Research and Technology of Agro-Environmental and Biological Sciences (CITAB), 
University of Trás-os-Montes and Alto Douro, UTAD, Quinta de Prados, 5001-911 Vila Real, 
Portugal 
f Veterinary Sciences Department, University of Trás-os-Montes and Alto Douro, UTAD, Quinta de Prados, 
5001-801 Vila Real, Portugal 
g CEBIMED, Faculty of Health Sciences, Fernando Pessoa University, Porto, Portugal 
 
Background/Objectives: Human Papillomavirus (HPV) is the most common sexual transmitted agent 
worldwide, being also responsible for 5 % of all human cancers.  Even though cervical cancer is 
thought to be reducing, HPV positive anogenital and head and neck cancers are regrettably 
increasing. Differences in the natural history of HPV have been observed by gender and anatomic 
sites of infection where epithelial backgrounds and tissue microenvironment may play a crucial role. 
The main goal of this study was to understand if E6, E7 and E5 oncoproteins may promote distinct 
roles in the carcinogenesis cascade in K14-HPV16 mice model base of tongue, anus and uterine 
cervix characterized by different tissue microenvironments. Methods: The base of the tongue, anus 
and uterine cervix samples were collected from 10 female 30-week-old K14-HPV16 transgenic mice. 
Histopathological analysis of the tissues was performed for tissue characterization. Tissue samples 
were classified as normal, hyperplasic, dysplastic and carcinoma.  The E6, E7 and E5 mRNA levels 
were quantified by real-time PCR being normalized by a combination of the best two housekeeping 
genes. Statistical analysis was performed using the IBM SPSS Statistics (Version 24.0). Mann-
Whitney tests were used to evaluate statistical differences in normalized relative expression (–ΔCt) 
of the E6, E7 and E5 genes among the different tissue samples. Results:  We observed a higher 
incidence of more advanced lesions, namely HSIL and carcinoma on the base of the tongue tissue 
samples in comparison with the anus where all lesions were hyperplasic. All the uterine cervix 
samples presented to be normal. Furthermore, the expression of the oncogenic HPV viral mRNA was 
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detected across tissues with no significant overexpression within the different lesions.  Conclusion: 
This study enlightens the proof of concept of an earlier and less-cofactor dependent carcinogenesis 
induced by HPV in oropharyngeal cancers in comparison with other anatomic localizations. In the 
base of the tongue, cancer was induced within the mice 30 weeks period, in comparison with the 
anus and uterine cervix, where HPV itself seems not to be sufficient to promote advanced lesions 
even though the expression of the viral mRNA´s are detected and similar within the tissues.  Future 
studies should focus on understanding the behaviour of the HPV oncoproteins and the related 
oncogenic pathways at multiple anatomic locations of infection, representing different tissue 
microenvironments. This might allow a better understanding of tissue-specific HPV-related 
carcinogenic steps and a consequent precision therapy.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Annexes 
 
 VI 
8.3. Poster presentation in the Aims Meeting 2019, 
Lisbon, Portugal  
 
K14-HPV16 MOUSE MODEL: A JOURNEY TOWARDS EARLY HPV-
INDUCED HEAD AND NECK VS ANAl, UTERINE AND BLADDER 
CARCINOGENESIS   
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a Molecular Oncology and Viral Pathology Group, IPO-Porto Research Center (CI-IPOP), Portuguese 
Institute of Oncology of Porto (IPO-Porto), Rua Dr. António Bernardino de Almeida, 4200-072 
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d LEPABE, Faculty of Engineering, University of Porto, Rua Dr. Roberto Frias s/n, 4200-465 Porto, Portugal 
e Center for the Research and Technology of Agro-Environmental and Biological Sciences (CITAB), 
University of Trás-os-Montes and Alto Douro, UTAD, Quinta de Prados, 5001-911 Vila Real, 
Portugal 
f Veterinary Sciences Department, University of Trás-os-Montes and Alto Douro, UTAD, Quinta de Prados, 
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Introduction: Differences in the natural history of HPV have been observed in the anatomic sites of 
infection, where epithelial backgrounds and tissue microenvironments may play a crucial role. The 
main goal of this study was to observe if E6, E7 and E5 HPV oncoproteins trigger distinct 
carcinogenic pathways in the K14-HPV16 mouse model, on the base of tongue, anus, uterine cervix, 
penis and bladder, which are characterized by different tissue microenvironments and epithelia. 
Methods: Samples from the base of the tongue, anus, uterine cervix and bladder were collected from 
ten K14-HPV16 female mice 30-week-old. The E6, E7 and E5 mRNA levels were quantified by RT-
PCR, after normalization using the best two housekeeping genes. Histopathological analysis of the 
tissues was performed for tissue characterization and classified as normal, hyperplastic, dysplastic 
and carcinoma. Statistical analysis was performed using the IBM SPSS Statistics. Kruskal-Wallis 
tests were used to evaluate statistical differences in normalized relative expression of E6, E7 and E5 
Results: The expression pattern of the oncogenic HPV viral mRNAs E6, E7 and E5 was similarly 
detected across the tissues (p>0,05), except in the bladder (p< 0.01). However, we observed a higher 
incidence of more advanced lesions, namely dysplasia and squamous cell carcinoma in the base of 
the tongue when compared with the anus, where hyperplasia was the most observed lesion. In uterine 
cervix and bladder samples, only normal epithelium was observed. Alongside, no significant 
difference of the transgene’s HPV mRNAs E6, E7 and E5 expression were found within the three 
types of lesions that were characterized in this study (p=0,831, p=0,670 and p=0,522 respectively). 
Annexes 
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Conclusion: This study suggests that the carcinogenesis induced by HPV in oropharyngeal cancers 
is less dependent on co-factors, compared with the other anatomic locations. In the base of the tongue, 
cancer was induced within the mice 30 weeks period, in comparison with the other anatomic 
locations, where HPV is not sufficient to promote advanced lesions even though the expression of 
the viral mRNAs was detected similarly within the tissues.  Future studies should focus on 
understanding the behaviour of the HPV oncoproteins at multiple anatomic locations of infection, 
representing different tissue microenvironments. This might allow a better understanding of tissue-
specific HPV carcinogenesis and the development of precision therapies. 
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